- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01867671
Peanut Oral Immunotherapy in Children (IMPACT)
Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)
Study Overview
Status
Conditions
Detailed Description
An initial oral food challenge (OFC) to 1 g of peanut flour (500 mg peanut protein) will be conducted. Participants must have a clinical reaction during this OFC to initiate study dosing. After the initial OFC, the study design includes four phases:
- Initial dose escalation (1 day): Peanut or placebo dosing will be given incrementally and increase every 20 minutes until a dose of 12 mg peanut flour (6 mg peanut protein) or placebo flour is given.
- Build-up (30 weeks): Initial observed dose administration of highest tolerated dose, followed by daily OIT at home with return visit every 2 weeks for dose escalation.
- Maintenance (104 weeks):The participant will continue on daily OIT with return visits every 13 weeks. At the end of this phase the participant will undergo a blinded OFC to 10 g peanut flour (5 g peanut protein).
- Avoidance (26 weeks): In this final phase participants will be seen every 13 weeks. At the completion of this phase participants will have a final blinded OFC to 10g peanut flour (5 g peanut protein).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- University of Arkansas for Medical Sciences: Arkansas Children's Hospital
-
-
California
-
Stanford, California, United States, 94040
- Stanford University School of Medicine
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Chapel-Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical history of peanut allergy or avoidance of peanut without ever having eaten peanut;
- Serum immunoglobulin E (IgE) to peanut of ≥5 kUA/L determined by UniCAP™, an in-vitro test system for diagnosis and monitoring of allergy and inflammation;
- Wheal ≥ 3mm on skin prick test to peanut extract compared to a negative control;
- A clinical reaction at or below ingestion of 1 g peanut flour (500 mg peanut protein) during screening OFC;
- Written informed consent from parent/guardian.
Exclusion Criteria:
- History of severe anaphylaxis with hypotension to peanut;
- Documented clinical history of allergy to oat;
- Suspected allergy to oat and a wheal ≥7mm on skin prick test to oat extract compared to a negative control;
- Chronic disease other than asthma, atopic dermatitis, rhinitis requiring therapy; e.g., heart disease or diabetes;
- Active eosinophilic gastrointestinal disease in the past 2 years;
- Participation in any interventional study for the treatment of food allergy in the 6 months prior to visit -1;
- Inhalant allergen immunotherapy that has not yet reached maintenance dosing;
- Severe asthma, as indicated by repeated hospitalizations or hospital emergency department visits;
- Moderate asthma defined according to National Asthma Education and Prevention Program Expert;
- Panel that requires more than fluticasone 440 mcg or its equivalent daily for adequate control;
- Inability to discontinue antihistamines for skin testing, OFC and the initial dose escalation;
- Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) in the 12 months prior to visit -1;
- Any systemic therapy which in the judgment of the investigator could be immunomodulatory (e.g. rituximab) in the 12 months prior to visit -1, systemic corticosteroid therapy of up to a total of three weeks is allowed;
- Use of any investigational drug in 90 days prior to visit -1;
- Plan to use any investigational drug during the study period;
- The presence of any medical condition that the investigator deems incompatible with participation in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Peanut Oral Immune Therapy (OIT)
Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
|
Used during initial dose escalation for doses 0.1 to 0.8 mg.
This will be used for the remainder of dose escalation, build-up, and maintenance.
|
Placebo Comparator: Peanut Placebo
Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks.
The placebo extract will be derived from oat flour source material.
|
Similar in appearance, texture, and taste to peanut liquid extract.
Similar in appearance, texture, and taste to peanut flour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Desensitized to Peanut Protein After 134 Weeks of Oral Immunotherapy (OIT)
Time Frame: Week 134
|
Definition of desensitized to peanut: A participant who passed the blinded (masked) oral food challenge (OFC) to10 grams of peanut flour (=5 grams of peanut protein) without significant symptoms.* *Significant symptoms include hives, wheezing, vomiting, or laryngeal edema. |
Week 134
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Tolerant Participants at Week 160
Time Frame: Week 160
|
Definition of Tolerant: A participant who passed the oral food challenge (OFC) to 10 grams of peanut flour (=5 grams of peanut protein).
|
Week 160
|
Count of Participants With Transient Desensitization
Time Frame: Week 134, Week 160
|
Definition of transient desensitization: A participant who passed the blinded (masked) oral food challenge (OFC) to 10 grams peanut flour (=5 grams peanut protein) at week 134 and failed the week 160 in the Peanut oral immunotherapy (OIT) group.
|
Week 134, Week 160
|
Highest Tolerated Cumulative Dose
Time Frame: Week 160
|
The highest tolerated cumulative dose of peanut protein during the blinded (masked) oral food challenge (OFC) at Week 160, analyzed within and between both placebo and peanut OIT groups. The highest cumulative dose of peanut protein tolerated for each participant was analyzed as a continuous outcome. Any randomized participant without an evaluable blinded (masked) OFC was imputed as not tolerant. For the continuous highest cumulative dose endpoint, this is defined as having a highest cumulative dose imputed as zero. |
Week 160
|
Percentage of Participants That Withdrew From the Study
Time Frame: Initial Dose Escalation through Week 160 (Tolerance Assessment)
|
Percentage of participants that withdrew from study participation, listed by study phase (at time of study withdrawal).
|
Initial Dose Escalation through Week 160 (Tolerance Assessment)
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Wesley Burks, MD, UNC Chapel-Hill
- Study Chair: Stacie M. Jones, MD, University of Arkansas
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAIT ITN050AD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Hypersensitivity
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
Baylor College of MedicineCompletedPeanut Allergic SubjectsUnited States
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
IgGenix Australia Pty LtdNot yet recruiting
-
DBV TechnologiesEnrolling by invitationPeanut AllergyUnited States
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
DBV TechnologiesCompleted
Clinical Trials on Peanut Oral Immunotherapy - Liquid Extract
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)CompletedFood Hypersensitivity | Peanut Hypersensitivity | Peanut Allergy | Food AllergyUnited States
-
Johns Hopkins UniversityCompleted
-
Guy's and St Thomas' NHS Foundation TrustKing's College London; Imperial College London; National Institute for Health...Unknown
-
Cambridge University Hospitals NHS Foundation TrustCompleted
-
Baylor College of MedicineCompletedPeanut Allergic SubjectsUnited States
-
University of North Carolina, Chapel HillCompletedFood HypersensitivityUnited States
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Murdoch Childrens Research InstituteNot yet recruiting
-
Massachusetts General HospitalEnrolling by invitation
-
Alton MeltonThe Cleveland ClinicActive, not recruiting